| 1 |
de Koning PJ, Kummer JA, de Poot SA, Quadir R, Higgins W, Worrall DM, and Bovenschen N. Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. PLoS ONE. 2011; 6:e22645. |
| 2 |
Hollestelle MJ, Lai KW, van Deuren M, Lenting PJ, de Groot PG, Sprong T, and Bovenschen N. Cleavage of von Willebrand factor by granzyme M destroys its factor VIII binding capacity. PLoS ONE. 2011; 6:e24216. |
| 3 |
van Domselaar R, and Bovenschen N. Cell death-independent functions of granzymes: hit viruses where it hurts. Rev Med Virol. 2011; 21:301-314. |
| 4 |
de Poot SA, Westgeest M, Hostetter DR, Van Damme P, Plasman K, Demeyer K, Broekhuizen R, Gevaert K, Craik CS, and Bovenschen N. Human and mouse granzyme M display divergent and species-specific substrate specificities. Biochem J. 2011; 437:431-442. |
| 5 |
van Tetering G, Bovenschen N, Meeldijk J, van Diest PJ, and Vooijs M. Cleavage of Notch1 by granzyme B disables its transcriptional activity. Biochem J. 2011; 437:313-322. |
| 6 |
Bovenschen N. LDL receptor polymorphisms revisited. Blood. 2010; 116:5439-5440 |
| 7 |
van Domselaar R, Philippen LE, Quadir R, Wiertz EJ, Kummer JA, and Bovenschen N. Noncytotoxic Inhibition of Cytomegalovirus Replication through NK Cell Protease Granzyme M-Mediated Cleavage of Viral Phosphoprotein 71. J Immunol. 2010; 185:7605-13 |
| 8 |
Bovenschen N, and Kummer JA. Orphan granzymes find a home. Immunol Rev. 2010; 235:117-127 |
| 9 |
van Domselaar R, de Poot SA, and Bovenschen N. Proteomic profiling of protease substrate specificity. Expert Rev Proteomics. 2010; 7:347-359 |
| 10 |
Hollestelle MJ, Sprong T, Bovenschen N, de Mast Q, van der Ven AJ, Joosten LA, Neeleman C, Hyseni A, Lenting PJ, de Groot PG, van Deuren M. Von Willebrand factor activation, granzyme-B and thrombocytopenia in meningococcal disease. J Thromb Haemost. 2010; 8:1098-1106 |
| 11 |
de Koning PJ, Tesselaar K, Bovenschen N, Çolak S, Quadir R, Volman TJ, and Kummer JA. Expression of the human cytotoxic protease granzyme M by lymphocyte subsets. Mol Immunol. 2010; 47:903-911 |
| 12 |
de Koning PJ, Kummer JA, and Bovenschen N. The biology of granzyme M: a serine protease with unique features. Crit Rev Immunol. 2009; 29:307-315 |
| 13 |
Bovenschen N, Quadir R, van den Berg AL, Brenkman AB, Vandenberghe I, Devreese B, Joore J, and Kummer JA. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. J Biol Chem. 2009; 284:3504-3512. |
| 14 |
Bovenschen N, de Koning PJ, Quadir R, Broekhuizen R, Damen JM, Froelich CJ, Slijper M, and Kummer JA. Natural killer cell protease granzyme M targets alpha-tubulin and disorganizes the microtubule network. J Immunol. 2008; 180:8184-8191. |
| 15 |
Kummer JA, Micheau O, Schneider P, Bovenschen N, Broekhuizen R, Quadir R, Strik MC, Hack CE, and Tschopp J. Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis. Cell Death Differ. 2007; 14:1486-1496. |
| 16 |
Bovenschen N, Mertens K, Hu L, Havekes LM, and van Vlijmen BJ. LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo. Blood. 2005; 106:906-912. |
| 17 |
Bovenschen N, Boertjes RC, van Stempvoort G, Voorberg J, Lenting PJ, Meijer AB, and Mertens K. Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII. J Biol Chem. 2003; 278:9370-9377. |
| 18 |
Bovenschen N, Herz J, Grimbergen JM, Lenting PJ, Havekes LM, Mertens K, and van Vlijmen BJ. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. Blood. 2003; 101:3933-3939. |
| 19 |
Bladergroen BA, Strik MC, Bovenschen N, van Berkum O, Scheffer GL, Meijer CJ, Hack CE, and Kummer JA. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol. 2001; 166:3218-3225. |